Trial Profile
Safety and Efficacy of Intratympanically Delivered Golimumab for Stabilization of Hearing in Patients With Autoimmune Inner Ear Disease: An Open-label Proof-of-concept Clinical Trial
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Apr 2015
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Autoimmune disorders; Ear disorders; Hearing loss; Sensorineural hearing loss
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 09 Apr 2015 New trial record